跳至主要内容
临床试验/NCT00207792
NCT00207792Unknown3 期

Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

Centre National de Greffe de Moelle Osseuse1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2005年7月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
发起方
入组人数
160
试验地点
1

研究概览

简要总结

The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear.

The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 45 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age: > 16 years and < 46 years
  • •Geno-identical allogeneic bone marrow transplantation
  • •Myeloablative conditioning regimen
  • •Haematological malignancies and acquired aplastic anemia
  • •Written and informed consent

排除标准

  • •ECOG performance score > 2
  • •T-cell depletion
  • •Serum creatinine level > 133 µmol/L
  • •Abnormal liver function
  • •Positive HIV test
  • •Pregnant women

研究者

发起方
Centre National de Greffe de Moelle Osseuse
申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验